<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03646331</url>
  </required_header>
  <id_info>
    <org_study_id>PXL008-022</org_study_id>
    <nct_id>NCT03646331</nct_id>
  </id_info>
  <brief_title>Bioequivalence of Imeglimin Tablet Formulations</brief_title>
  <official_title>A Phase I, Open-label, Randomised, Single-centre, 2-way Crossover Bioequivalence Study Comparing 2 Formulations of Imeglimin After Single Oral Doses in Healthy Caucasian Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poxel SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poxel SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label assessment of the bioequivalence of two 500 mg-tablet formulations of
      imeglimin (Tablet A [reference product] and Tablet B [test product]), in at least 16 healthy
      Caucasian volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 3, 2018</start_date>
  <completion_date type="Actual">October 2, 2018</completion_date>
  <primary_completion_date type="Actual">September 27, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pk parameters of imeglimin</measure>
    <time_frame>from dosing up to 48h</time_frame>
    <description>Cmax: peak plasma concentration after dosing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK parameters of Imeglimin</measure>
    <time_frame>from dosing up to 48h</time_frame>
    <description>AUC last: area Under the concentration time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment emergent adverse events (Safety and tolerability)</measure>
    <time_frame>From Day 1 to Day 15</time_frame>
    <description>Incidence of treatment emergent adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Bioequivalence</condition>
  <arm_group>
    <arm_group_label>Tablet A in Session 1 and Tablet B in Session 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablet A = reference product Tablet B = test product</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tablet B in Session 1 and Tablet A in Session 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tablet A = reference product Tablet B = test product</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imeglimin Reference product</intervention_name>
    <description>Reference product</description>
    <arm_group_label>Tablet A in Session 1 and Tablet B in Session 2</arm_group_label>
    <arm_group_label>Tablet B in Session 1 and Tablet A in Session 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imeglimin</intervention_name>
    <description>Test product (new formulation tablet)</description>
    <arm_group_label>Tablet A in Session 1 and Tablet B in Session 2</arm_group_label>
    <arm_group_label>Tablet B in Session 1 and Tablet A in Session 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI : 18.5-29.9

          -  Body weight â‰¥ 60 kg

          -  willing to use reliable contraception

          -  able to give fully informed written consent.

        Exclusion Criteria:

          -  Positive tests for hepatitis B &amp; C, HIV

          -  severe adverse reaction to any drug; sensitivity to trial medication and/or food
             allergies

          -  drug or alcohol abuse

          -  smoking of more than 5 cigarettes daily or drinking more than 5 cups of caffeinated
             drinks daily

          -  over-the-counter medication, vitamins and herbal remedies, or prescribed medication in
             the 20 days before the first dose of trial medication (with the exception of
             paracetamol [acetaminophen] and oral contraception);

          -  participation in other clinical trials of unlicensed medicines, or loss of more than
             400 mL blood, within the previous 3 months

          -  vital signs outside the acceptable range

          -  clinically relevant abnormal findings at the screening assessment; estimated
             glomerular filtration rate (eGFR) at screening &lt; 80 mL/min/1.73 m2

          -  acute or chronic illness

          -  clinically relevant abnormal medical history or concurrent medical condition;

          -  surgery or medical condition that might affect the absorption of medicines;

          -  possibility that volunteer will not cooperate

          -  pre-menopausal females who are pregnant or lactating, or who are sexually active and
             not using a reliable method of contraception;

          -  objection by the volunteer's General Practitioner (GP).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hammersmith Medicines Research (HMR)</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>August 23, 2018</study_first_submitted>
  <study_first_submitted_qc>August 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2018</study_first_posted>
  <last_update_submitted>January 10, 2019</last_update_submitted>
  <last_update_submitted_qc>January 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

